

IN THE CLAIMS:

Please cancel claims 3 and 24-25 without prejudice or disclaimer.

Please amend claims 1-2, 10-11, 16, 21 and 23-24 in the following manner:

A¹

1. (Amended) A liposomal topotecan unit dosage form, said unit dosage form comprising:
2 a lipid; and
3 a topotecan dosage of from about 0.01 mg/M²/dose to about 7.5
4 mg/M²/dose, wherein said liposomal topotecan unit dosage form has a drug:lipid ratio by
5 weight of about 0.05 to about 0.2 and wherein said lipid comprises a mixture of
6 sphingomyelin and cholesterol.

1. (Amended) The liposomal topotecan unit dosage form of claim 1,
2 wherein said drug:lipid ratio by weight is about 0.05 to about 0.15.

A²

10. (Amended) The liposomal topotecan formulation of claim 8,
1 comprising a drug:lipid ratio by weight of about 0.05 to about 0.2.

11. (Amended) The liposomal topotecan formulation of claim 10,
2 wherein said drug:lipid ratio by weight is about 0.05 to about 0.15.

A³

16. (Amended) A method of treating solid tumors in a mammal, said method comprising:
2 administering to said mammal having a solid tumor of the lung, mammary
3 and/or colon a liposomal topotecan formulation having a drug:lipid ratio by weight of
4 about 0.05 to about 0.2.